XL184 (cabozantinib) for medullary thyroid carcinoma

Author： Durante Cosimo Russo Diego Verrienti Antonella Filetti Sebastiano

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.3, 2011-03, pp. : 407-413

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Surgery for lymph node metastases of medullary thyroid carcinoma: A review

By Jin Linda X. Moley Jeffrey F.

Cancer, Vol. 122, Iss. 3, 2016-02 ,pp. : 358-366

Blackwell Publishing

Access to resources Recommend Favorite

Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer

By Karras Spyridon Pontikides Nikolaos Krassas Gerasimos E

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 4, 2013-04 ,pp. : 507-515

Informa Healthcare

Access to resources Recommend Favorite

Vandetanib: In Medullary Thyroid Cancer

By Frampton James E.

Drugs, Vol. 72, Iss. 10, 2012-07 ,pp. : 1423-1436

Adis International

Access to resources Recommend Favorite

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma

By Krampitz Geoffrey W. Norton Jeffrey A.

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1920-1931

Blackwell Publishing

Access to resources Recommend Favorite

Thyroid Carcinoma

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 5, Iss. 6, 2007-07 ,pp. : 568-568

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite